Pentavalent vaccine

On the basis of both seroresponse and GMT ratios against serogroups A, C, W, Y, and X, noninferiority was demonstrated in all three age subgroups -- 2 to 10 years, 11 to 17 years, and 18 to 29 years. The trial's findings are expected to support the licensure and prequalification of NmCV-5 by the World Health Organization (WHO) as the first vaccine to target the emerging serogroup X, the researchers detailed in the For seroresponse measured at 28 days, the overall difference with NmCV-5 versus MenACWY-D, respectively, ranged from 1.2 percentage points (96% CI -0.3 to 3.1) for serogroup W to 20.5 percentage points (96% CI 15.4-25.6) for serogroup A, and the pentavalent vaccine also elicited a strong immune response for serogroup X: • Serogroup A: 70.5% vs 50.0% • Serogroup C: 97.9% vs 95.5% • Serogroup W: 98.5% vs 97.4% • Serogroup Y: 97.0% vs 92.0% • Serogroup X: 97.2% vs 9.5% GMT ratios favored the NmCV-5 vaccine across all serogroups of Neisseria meningitidis, the predominant cause of meningitis epidemics, ranging from 1.7 (95% CI 1.5-1.9) for serogroup A to 2.8 (95% CI 2.3-3.5) for serogroup C, with serogroup X responses also hitting prespecified criteria for noninferiority for both measures. "On the basis of these trial data, NmCV-5 may emerge as a tool to support meningococcal disease control, particularly across the meningitis belt of sub-Saharan Africa, and thus may contribute to epidemic elimination and the other goals of the global road map for the An estimated 2.5...

For media and investors only Issued: London, UK • The Phase 3 study is evaluating the safety, tolerability and immunogenicity of GSK’s MenABCWY vaccine candidate compared to Bexsero and Menveo in adolescents and young adults • Study investigators to enroll 3,650 participants aged 10-25 years in the U.S., Canada, Europe, Turkey and Australia GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that patient dosing has begun in a phase III clinical programme investigating its 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo. Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D for GSK, said: “Entering the final stage of clinical trials with our 5-in-1, MenABCWY vaccine candidate is a major step toward GSK’s goal of reducing meningococcal disease around the world. This vaccine candidate builds on the heritage of Bexsero and Menveo and we would like to thank all the scientific researchers, medical partners, advocates and families around the world who also hope for a successful outcome.” The initial Phase 3 studies [1] (NCT04502693) will be conducted in individuals aged 10-25 years in the United States, Canada, Europe, Turkey and Australia and the study investigators will enroll 3,650 participants. The trial will evaluate safety, tolerability and immunogenicity of GSK’s 5-in-1, MenABCWY vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo. Helping protect adolescents and young adu...

Vaccine Schedules • • • • • • • *Please note that the first dose should be given as soon as possible. Additional doses require minimum time intervals between doses in order for the vaccine to be effective. 3-Dose Vaccine Series for Infants (Including the "Birth Dose") Since 1991, ALL medically stable infants with a birth weight of at least 2,000 g in the U.S. are recommended to receive the first dose of hepatitis B vaccine within 24 hours of birth. The additional 2 doses are given at 1 month and 6 months of age. 4-Dose Vaccine Combination Series for Infants (Pentavalent or Hexavalent) Combination vaccines, such as the pentavalent and hexavalent vaccines, include protection against 5 or 6 diseases, including hepatitis B. The first shot is usually given at 6 weeks of age, but in order to protect infants from hepatitis B beginning at birth, a monovalent or single dose of the hepatitis B vaccine is also recommended within 24 hours of birth. The hepatitis B vaccine series can then be completed with the pentavalent or hexavalent vaccine with the recommended schedule. NEWS: VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults *Please note that the first dose should be given as soon as possible. Additional doses require minimum time intervals between doses in order for the vaccine to be effective. 3-Dose Vaccine Series for Children and Adults The hepatitis B vaccine is an injection (or shot) that is generally given in the arm as a three-do...

• Quintavax: • Pentavac: A pentavalent vaccine, also known as a 5-in-1 vaccine, is a Pentavalent vaccine frequently refers to the 5-in-1 vaccine protecting against Another pentavalent vaccine is the 5-in-1 vaccine that protects against diphtheria, tetanus, whooping cough, Haemophilus influenza type B, which was used in the UK until 2017, following which a By 2013, pentavalent vaccines accounted for 100% of the Safety [ ] During studies and tests, the History [ ] In October 2004, the In September 2006, the first pentavalent vaccine formulation received pre-qualification approval from the In 2012, By 2013, pentavalent vaccines accounted for 100% of the In 2014, South Sudan became the last of the 73 Society and culture [ ] In May 2010, In November 2010, the public-private consortium High-income countries tend to use alternative formulations using acellular pertussis (Pa), which has a more favourable profile of side-effects, rather than whole-cell pertussis components. • All pentavalent vaccine prices fell and India [ ] In 2013, it was found that Pentavac PFS vaccines were being supplied with two different sets of packaging: One set with manufacturing and expiry dates was being provided to [ citation needed] Sri Lanka [ ] Bhutan [ ] Vietnam [ ] Between December 2012 and March 2013 nine deaths were reported in After a review of the cases conducted by national experts together with staff from WHO and UNICEF and an independent clinician, no link with vaccination could be identifi...

• Clinical Trials • Your participation makes a difference • Designed to improve kids' health • Sharing our Results • Building Trust • Equity and Representation • Trial Result Summaries • Possible Treatment Options • Find a Trial • Areas of Focus • Smaller populations but big impact • Extending lifespans worldwide • Treatment at the molecular level • Preventing the spread of infections • The science of optimism • Combatting an evolving risk • Areas of Innovation • Breakthroughs become treatments • The next generation of science • Developing tailored medicines • Protecting newborns at the start • Unleashing the next wave of scientific innovations • Diseases & Conditions • Coronavirus Resources • Product Pipeline • Research Sites • • How Drugs are Made • Learn the difference • Cures found in nature • Maintaining the highest standards • Strategic manufacturing locations • Where medicine is made in the U.S. • Medicine Safety • Learning to be well • Learning about treatment decisions • Helping others by reporting side effects • Preventing medication errors • • Preventing medication errors • • Product List • Product Contacts • PfizerPro for Professionals • Patient Assistance Programs • Distributors • • • People • Our senior-most leadership • The people steering our company • Our experts making discoveries • Our patients • Our colleagues • Responsibility • Each of us is responsible • Everyone has something to offer • • Our responsiblity to the environment • Meeting urgent needs wo...